QTc Prolongation due to Psychotropic Drugs Intoxication and Its Risk Assessment
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: The aims of the present study were twofold. First, the research investigated the effect of an individual’s risk factors and the prevalence of psychotropic drugs on QTc prolongation, TdP (torsades de pointes), and death. Second, the study compared the risk scoring systems (the Mayo Pro-QT risk score and the Tisadale risk score) on QTc prolongation. Methods: The medical records of intoxicated patients who visited the emergency department between March 2010 and February 2019 were reviewed retrospectively. Among 733 patients, the present study included 426 psychotropic drug-intoxicated patients. The patients were categorized according to the QTc value. The known risk factors of QTc prolongation were examined, and the Mayo Pro-QT risk score and the Tisadale risk score were calculated. The analysis was performed using multiple logistic regression, Spearman correlation, and ROC (receiver operating characteristic). Results: The numbers in the mild to moderate group (male: 470≤QTc<500 ms, female: 480≤QTc<500 ms) and severe group (QTc≥500 ms or increase of QTc at least 60ms from baseline, both sex) were 68 and 95, respectively. TdP did not occur, and the only cause of death was aspiration pneumonia. The statically significant risk factors were multidrug intoxications of TCA (tricyclic antidepressant), atypical antipsychotics, an atypical antidepressant, panic disorder, and hypokalemia. The Tisadale risk score was larger than the Mayo Pro-QT risk score. Conclusion: Multiple psychotropic drugs intoxication (TCA, an atypical antidepressant, and atypical antipsychotics), panic disorder, and hypokalemia have been proven to be the main risk factors of QTc prolongation, which require enhanced attention. The present study showed that the Tisadale score had a stronger correlation and predictive accuracy for QTc prolongation than the Mayo Pro-QT score. As a result, the Tisadale risk score is a crucial assessment tool for psychotropic drug-intoxicated patients in a clinical setting.
Abstract
Purpose: The aims of the present study were twofold. First, the research investigated the effect of an individual’s risk factors and the prevalence of psychotropic drugs on QTc prolongation, TdP (torsades de pointes), and death. Second, the study compared the risk scoring systems (the Mayo Pro-QT risk score and the Tisadale risk score) on QTc prolongation. Methods: The medical records of intoxicated patients who visited the emergency department between March 2010 and February 2019 were reviewed retrospectively. Among 733 patients, the present study included 426 psychotropic drug-intoxicated patients. The patients were categorized according to the QTc value. The known risk factors of QTc prolongation were examined, and the Mayo Pro-QT risk score and the Tisadale risk score were calculated. The analysis was performed using multiple logistic regression, Spearman correlation, and ROC (receiver operating characteristic). Results: The numbers in the mild to moderate group (male: 470≤QTc<500 ms, female: 480≤QTc<500 ms) and severe group (QTc≥500 ms or increase of QTc at least 60ms from baseline, both sex) were 68 and 95, respectively. TdP did not occur, and the only cause of death was aspiration pneumonia. The statically significant risk factors were multidrug intoxications of TCA (tricyclic antidepressant), atypical antipsychotics, an atypical antidepressant, panic disorder, and hypokalemia. The Tisadale risk score was larger than the Mayo Pro-QT risk score. Conclusion: Multiple psychotropic drugs intoxication (TCA, an atypical antidepressant, and atypical antipsychotics), panic disorder, and hypokalemia have been proven to be the main risk factors of QTc prolongation, which require enhanced attention. The present study showed that the Tisadale score had a stronger correlation and predictive accuracy for QTc prolongation than the Mayo Pro-QT score. As a result, the Tisadale risk score is a crucial assessment tool for psychotropic drug-intoxicated patients in a clinical setting.
참고문헌 (37)
- "Organisation for Economic Co-operation and Development"[URL]
- "2020- 2018 National Survey on Suicide South Korea Ministry of Health and Welfare"[URL]
- Talia L. Brown, "Access to Psychotropic Medication via Prescription Is Associated With Choice of Psychotropic Medication as Suicide Method", The Journal of Clinical Psychiatry, 79(6) (2018), Physicians Postgraduate Press, Inc[DOI]
- Pentti M. Rautaharju, "AHA", ACCF, Circulation, pp.2009, 119(10)[DOI]
- Peter M. Haddad, "Antipsychotic-Related QTc Prolongation, Torsade de Pointes and Sudden Death", Drugs, 62(11), pp.1649~1671 (2002), Springer Science and Business Media LLC[DOI]
- Chan A, "Drug-induced QT prolongation and torsades de pointes : evaluation of a QT nomogram", QJM, 100(10), pp.609~615 (2007)[DOI]
- Y. G. Yap, "Drug induced QT prolongation and torsades de pointes", Heart, 89(11), pp.1363~1372 (2003), BMJ[DOI]
- Peter J. Schwartz, "Predicting the Unpredictable", Journal of the American College of Cardiology, 67(13), pp.1639~1650 (2016), Elsevier BV[DOI]
- Alastair J.J. Wood, "Drug-Induced Prolongation of the QT Interval", New England Journal of Medicine, 350(10), pp.1013~1022 (2004), Massachusetts Medical Society[DOI]
- Barbara J. Drew, "Prevention of Torsade de Pointes in Hospital Settings", Circulation, 121(8), pp.1047~1060 (2010), Ovid Technologies (Wolters Kluwer Health)[DOI]
- "QTdrugs List"[URL]
- "Korea Pharmaceutical Information Center"[URL]
- Kristina H. Haugaa, "Institution-Wide QT Alert System Identifies Patients With a High Risk of Mortality", Mayo Clinic Proceedings, 88(4), pp.315~325 (2013), Elsevier BV[DOI]
- James E. Tisdale, "Development and Validation of a Risk Score to Predict QT Interval Prolongation in Hospitalized Patients", Circulation: Cardiovascular Quality and Outcomes, 6(4), pp.479~487 (2013), Ovid Technologies (Wolters Kluwer Health)[DOI]
- Li M, "Drug-Induced QT Prolongation And Torsades de Pointes", PT, 42(7), pp.473~477 (2017)
- W REDFERN, "Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development", Cardiovascular Research, 58(1), pp.32~45 (2003), Oxford University Press (OUP)[DOI]
- Raymond L. Woosley, "Assessing cardiovascular drug safety for clinical decision-making", Nature Reviews Cardiology, 10(6), pp.330~337 (2013), Springer Science and Business Media LLC[DOI]
- JG Reilly, "QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients", The Lancet, 355(9209), pp.1048~1052 (2000), Elsevier BV[DOI]
- V. M. Castro, "QT interval and antidepressant use: a cross sectional study of electronic health records", BMJ, 346, pp.f288~f288 (2013), BMJ[DOI]
- Charlotte van Noord, "Psychotropic Drugs Associated With Corrected QT Interval Prolongation", Journal of Clinical Psychopharmacology, 29(1), pp.9~15 (2009), Ovid Technologies (Wolters Kluwer Health)[DOI]
- Natalia M. Jasiak, "Risk of QT", QTc Prolongation Among Newer Non-SSRI Antidepressants, 2014, pp.48(12), 1620~1628[DOI]
- Yuji Ozeki, "QTc prolongation and antipsychotic medications in a sample of 1017 patients with schizophrenia", Progress in Neuro-Psychopharmacology and Biological Psychiatry, 34(2), pp.401~405 (2010), Elsevier BV[DOI]
- Edmund P. Harrigan, "A Randomized Evaluation of the Effects of Six Antipsychotic Agents on QTc, In the Absence and Presence of Metabolic Inhibition", Journal of Clinical Psychopharmacology, 24(1), pp.62~69 (2004), Ovid Technologies (Wolters Kluwer Health)[DOI]
- Michela Sala, "QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy", Annals of General Psychiatry, 4(1), pp.1~ (2005), Springer Science and Business Media LLC[DOI]
- Robert Pohl, "QT interval variability in panic disorder patients after isoproterenol infusions", The International Journal of Neuropsychopharmacology, 4(01) (2001), Oxford University Press (OUP)[DOI]
- Igor A Kelmanson, "High anxiety in clinically healthy patients and increased QT dispersion: A meta-analysis", European Journal of Preventive Cardiology, 21(12), pp.1568~1574 (2013), Oxford University Press (OUP)[DOI]
- Monitillo F, "Ventricular repolarization measures for arrhythmic risk stratification", World J Cardiol, 8(1), pp.57~73 (2016)[DOI]
- Baumert M, "QT interval variability in body surface ECG : measurement, physiological basis, and clinical value : position statement and consensus guidance endorsed by the European Heart Rhythm Association jointly with the ESC Working Group on Cardiac Cellular Electrophysiology", Europace, 18(6), pp.925~944 (2016)[DOI]
- Kevin Wei, "Association between QT dispersion and autonomic dysfunction in patients with diabetes mellitus", Journal of the American College of Cardiology, 26(4), pp.859~863 (1995), Elsevier BV[DOI]
- (o) dependence of the rapid component of the delayed rectifier K+ current in cardiac cells, "Circulation Research", 1997, 782~789, pp.Ovid Technologies (Wolters Kluwer Health), 10.1161[DOI]
- Hirotaka Numaguchi, "A sensitive mechanism for cation modulation of potassium current", Nature Neuroscience, 3(5), pp.429~430 (2000), Springer Science and Business Media LLC[DOI]
- François R. Girardin, "Drug-Induced Long QT in Adult Psychiatric Inpatients: The 5-Year Cross-Sectional ECG Screening Outcome in Psychiatry Study", American Journal of Psychiatry, 170(12), pp.1468~1476 (2013), American Psychiatric Association Publishing[DOI]
- Wanda Shao, "QTc Prolongation Associated With Psychiatric Medications", Journal of Clinical Psychopharmacology, 39(1), pp.72~77 (2019), Ovid Technologies (Wolters Kluwer Health)[DOI]
- Sarganas G, "Epidemiology of symptomatic drug-induced long QT syndrome and Torsade de Pointes in Germany", Europace, 16(1), pp.101~108 (2014)[DOI]
- Luiz Belardinelli, "Assessing predictors of drug-induced torsade de pointes", Trends in Pharmacological Sciences, 24(12), pp.619~625 (2003), Elsevier BV[DOI]
- Scott R. Beach, "QT Prolongation, Torsades de Pointes, and Psychotropic Medications: A 5-Year Update", Psychosomatics, 59(2), pp.105~122 (2018), Elsevier BV[DOI]
- Geoffrey K. Isbister, "Activated Charcoal Decreases the Risk of QT Prolongation After Citalopram Overdose", Annals of Emergency Medicine, 50(5), pp.593~600.e46 (2007), Elsevier BV[DOI]